[肾素抑制剂——动脉高血压治疗的新方向]

[Renin inhibitors--new direction in the treatment of arterial hypertension].

作者信息

Vasiuk Iu A, Sadulaeva I A, Iushchuk E N, Trofimenko O S, Chirkov M V, Fedoseeva V S, Kulikov K G

出版信息

Ter Arkh. 2010;82(9):53-9.

Abstract

The paper covers current problems in the treatment of arterial hypertension. Renin is an important and promising therapeutic target. The direct renin inhibitor aliskiren (Rasilez) is a promising current effective antihypertensive agent that has cardio- and nephroprotective effects. The paper considers a number of clinical studies that have proven the antihypertensive effect of aliskiren and revealed its benefits versus other drugs recommended for blood pressure lowering. It is assumed that this agent may be used in combinations with angiotensin-converting enzyme inhibitors, thiazide or thiazide-like diuretics, and calcium antagonists. Moreover, aliskiren neutralizes the effect of feedback in the compensatory increase in the activity of plasma renin.

摘要

本文涵盖了动脉高血压治疗中的当前问题。肾素是一个重要且有前景的治疗靶点。直接肾素抑制剂阿利吉仑（Rasilez）是一种有前景的当前有效的抗高血压药物，具有心脏和肾脏保护作用。本文考虑了一些临床研究，这些研究证实了阿利吉仑的抗高血压作用，并揭示了其相对于其他推荐用于降低血压的药物的益处。据推测，该药物可与血管紧张素转换酶抑制剂、噻嗪类或噻嗪样利尿剂以及钙拮抗剂联合使用。此外，阿利吉仑可中和血浆肾素活性代偿性增加中的反馈作用。